Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Andy Smith

Latest From Andy Smith

Stock Watch: Moderna Shares Soar While Pfizer Slides

The stock price performances of the top two coronavirus vaccine producers are inversely correlated to their sales and pipelines. There seems to be an expectation of declining coronavirus vaccine sales for some, but not for others.

Stock Watch Coronavirus COVID-19

Stock Watch: How The Pandemic Impact On Pharma’s Value Chain Is Mutating

From clinical trials to in-person sales calls, the pharmaceutical value chain has been tested by the COVID-19 pandemic, but has held up. Nevertheless, recent friction within this chain may be more than a passing irritation.

Distribution Coronavirus COVID-19

Stock Watch: The Biotech Departure Lane From Europe

It is not only gene therapy companies that have found European payers hard to convince of the value of their products. Amarin’s proposed European pricing may lead to another US company exit.

Pricing Strategies Reimbursement

Stock Watch: Oncology After The Pandemic

Big pharmaceutical franchises may be recovering from the pandemic, but the extent of the untreated backlog of cancer patients from 2020 is still an important unknown driver even after second-quarter earnings season, and smaller cancer companies may still be bearing the brunt of COVID-19’s effects.

Stock Watch Commercial

Stock Watch: Donanemab Provides Cover For Lilly’s Second-Quarter Insulin Challenge

Lilly’s second-quarter earnings announcement relegated its core business in favor of its experimental Alzheimer’s disease drug. This diverted attention away from competitive reimbursement challenges that may be affecting its insulin business.

Stock Watch Sales & Earnings

Stock Watch: Vaccines Dominate Second-Quarter Earnings

Pfizer’s earnings were skewed by its coronavirus vaccine for the second quarter running while GSK’s vaccine sales were helped by the catch-up on pediatric immunization schedules. Sales of influenza vaccines may come to the fore in the second half.

Sales & Earnings Stock Watch
See All
UsernamePublicRestriction

Register